NCT06807021View on ClinicalTrials.gov

Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

October 15, 2026

Study Completion Date

November 6, 2026

Conditions
Burn ScarBurn Wound
Interventions
DRUG

IP1 control cream (Vehicle base)

Without FS2

DRUG

IP2 - 0.5% w/w FS2

FS2 in pharmaceutical compounding base

Trial Locations (2)

T6G 2B7

University of Alberta, Division of Plastic Surgery, Edmonton

L8L 2X2

Centre for Burn Research - Hamilton Health Sciences, Hamilton

All Listed Sponsors
collaborator

Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

NETWORK

lead

Birch BioMed Inc

INDUSTRY